Literature DB >> 11162091

Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.

A A Stoop1, E Eldering, T R Dafforn, R J Read, H Pannekoek.   

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is a member of the serine protease inhibitor (serpin) superfamily. Its highly mobile reactive-center loop (RCL) is thought to account for both the rapid inhibition of tissue-type plasminogen activator (t-PA), and the rapid and spontaneous transition of the unstable, active form of PAI-1 into a stable, inactive (latent) conformation (t(1/2) at 37 degrees C, 2.2 hours). We determined the amino acid residues responsible for the inherent instability of PAI-1, to assess whether these properties are independent and, consequently, whether the structural basis for inhibition and latency transition is different. For that purpose, a hypermutated PAI-1 library that is displayed on phage was pre-incubated for increasing periods (20 to 72 hours) at 37 degrees C, prior to a stringent selection for rapid t-PA binding. Accordingly, four rounds of phage-display selection resulted in the isolation of a stable PAI-1 variant (st-44: t(1/2) 450 hours) with 11 amino acid mutations. Backcrossing by DNA shuffling of this stable mutant with wt PAI-1 was performed to eliminate non-contributing mutations. It was shown that the combination of mutations at positions 50, 56, 61, 70, 94, 150, 222, 223, 264 and 331 increases the half-life of PAI-1 245-fold. Furthermore, within the limits of detection the stable mutants isolated are functionally indistinguishable from wild-type PAI-1 with respect to the rate of inhibition of t-PA, cleavage by t-PA, and binding to vitronectin. These stabilizing mutations constitute largely reversions to the stable "serpin consensus sequence" and are located in areas implicated in PAI-1 stability (e.g. the vitronectin-binding domain and the proximal hinge). Collectively, our data provide evidence that the structural requirements for PAI-1 loop insertion during latency transition and target proteinase inhibition can be separated. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162091     DOI: 10.1006/jmbi.2000.4356

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  10 in total

Review 1.  Laboratory-directed protein evolution.

Authors:  Ling Yuan; Itzhak Kurek; James English; Robert Keenan
Journal:  Microbiol Mol Biol Rev       Date:  2005-09       Impact factor: 11.056

2.  A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.

Authors:  Christine R Schar; Grant E Blouse; Kenneth H Minor; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

Review 3.  Functional stability of plasminogen activator inhibitor-1.

Authors:  Songul Yasar Yildiz; Pinar Kuru; Ebru Toksoy Oner; Mehmet Agirbasli
Journal:  ScientificWorldJournal       Date:  2014-10-15

Review 4.  Therapeutic SERPINs: Improving on Nature.

Authors:  Coen Maas; Steven de Maat
Journal:  Front Cardiovasc Med       Date:  2021-03-31

Review 5.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22

6.  Deep mutational scanning of the plasminogen activator inhibitor-1 functional landscape.

Authors:  Zachary M Huttinger; Laura M Haynes; Andrew Yee; Colin A Kretz; Matthew L Holding; David R Siemieniak; Daniel A Lawrence; David Ginsburg
Journal:  Sci Rep       Date:  2021-09-22       Impact factor: 4.379

7.  Transgenic overexpression of a stable Plasminogen Activator Inhibitor-1 variant.

Authors:  Abigail T Fahim; He Wang; Jining Feng; David Ginsburg
Journal:  Thromb Res       Date:  2008-09-05       Impact factor: 3.944

8.  Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.

Authors:  Qingcai Wang; Shmuel Shaltiel
Journal:  BMC Biochem       Date:  2003-07-08       Impact factor: 4.059

9.  Phage display of the serpin alpha-1 proteinase inhibitor randomized at consecutive residues in the reactive centre loop and biopanned with or without thrombin.

Authors:  Benjamin M Scott; Wadim L Matochko; Richard F Gierczak; Varsha Bhakta; Ratmir Derda; William P Sheffield
Journal:  PLoS One       Date:  2014-01-10       Impact factor: 3.240

10.  Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis.

Authors:  Varsha Bhakta; Mostafa Hamada; Amy Nouanesengsy; Jessica Lapierre; Darian L Perruzza; William P Sheffield
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.